Institutional Manager · CIK 0001974915
Vestal Point Capital, LP
NEW YORK, NY · File #028-23784
Latest AUM
$2.94B
Positions
76
Top-10 Concentration
52.2%
Filings
8
Portfolio Value Over Time
2024-03
2024-06
2024-09
2024-12
2025-03
2025-06
2025-09
2025-12
Biggest QoQ Changes
Ranked by conviction flow (share change × current price) so mark-to-market moves don't dominate. Price effect column shows how much of the $ change was just the stock moving.
| Action | Issuer | Ticker / CUSIP | Δ Shares | Flow ($) | Price Effect |
|---|---|---|---|---|---|
| NEW | Invesco QQQ Trust Series 1 | IVZ | +350,000 | +$215.0M | $0 |
| NEW | Terns Pharmaceuticals Inc | TERN | +4,500,000 | +$181.8M | $0 |
| ADD | BioMarin Pharmaceutical Inc | BMRN | +2,170,000 | +$129.0M | +$4.4M |
| ADD | Abivax SA | AAVXF | +900,000 | +$121.4M | +$50.0M |
| ADD | Arcellx Inc | ACLX | +1,675,000 | +$109.2M | -$21.1M |
| REDUCE | Nuvalent Inc | NUVL | -1,054,000 | -$106.0M | +$15.5M |
| REDUCE | Ascendis Pharma A/S | ASND | -425,000 | -$90.6M | +$8.7M |
| NEW | Merck & Co Inc | MRK | +775,000 | +$81.6M | $0 |
| EXITED | Amicus Therapeutics Inc | 03152W109 | -9,750,000 | -$76.8M | $0 |
| EXITED | Ionis Pharmaceuticals Inc | 462222100 | -1,075,000 | -$70.3M | $0 |
Sector Allocation
Filing History
- 13F HOLDINGS REPORTQ/E Dec 202576 pos · $2.94B
- 13F HOLDINGS REPORTQ/E Sep 202581 pos · $2.21B
- 13F HOLDINGS REPORTQ/E Jun 202572 pos · $1.90B
- 13F HOLDINGS REPORTQ/E Mar 202563 pos · $1.40B
- 13F HOLDINGS REPORTQ/E Dec 202473 pos · $1.69B
- 13F HOLDINGS REPORTQ/E Sep 202469 pos · $1.32B
- 13F HOLDINGS REPORTQ/E Jun 202460 pos · $1.34B
- 13F HOLDINGS REPORTQ/E Mar 202458 pos · $1.21B
Top 20 Holdings — Dec 2025
| # | Issuer | Ticker | Shares | Value | % of Portfolio |
|---|---|---|---|---|---|
| 1 | Abivax SA | AAVXF | 1,900,000 | $256.2M | 9.06% |
| 2 | Invesco QQQ Trust Series 1 | IVZ | 350,000 | $215.0M | 7.60% |
| 3 | Arcellx Inc | ACLX | 2,925,000 | $190.7M | 6.74% |
| 4 | Terns Pharmaceuticals Inc | TERN | 4,500,000 | $181.8M | 6.43% |
| 5 | BioMarin Pharmaceutical Inc | BMRN | 3,000,000 | $178.3M | 6.31% |
| 6 | Globus Medical Inc | GMED | 1,275,000 | $111.3M | 3.94% |
| 7 | Nurix Therapeutics Inc | NRIX | 4,690,000 | $89.0M | 3.15% |
| 8 | Alcon AG | ALC | 1,105,000 | $87.1M | 3.08% |
| 9 | Dexcom Inc | DXCM | 1,275,000 | $84.6M | 2.99% |
| 10 | Merck & Co Inc | MRK | 775,000 | $81.6M | 2.88% |
| 11 | Taysha Gene Therapies Inc | TSHA | 13,750,000 | $75.6M | 2.67% |
| 12 | Abbott Laboratories | ABLZF | 600,000 | $75.2M | 2.66% |
| 13 | Immatics NV | IMTX | 6,125,000 | $64.3M | 2.27% |
| 14 | Tyra Biosciences Inc | TYRA | 2,425,000 | $63.8M | 2.25% |
| 15 | Bicara Therapeutics Inc | BCAX | 3,575,000 | $60.2M | 2.13% |
| 16 | Arrowhead Pharmaceuticals Inc | ARWR | 900,000 | $59.8M | 2.11% |
| 17 | Enliven Therapeutics Inc | ELVN | 3,830,000 | $59.0M | 2.09% |
| 18 | Disc Medicine Inc | IRON | 735,000 | $58.4M | 2.06% |
| 19 | Jazz Pharmaceuticals PLC | JAZZ | 290,000 | $49.3M | 1.74% |
| 20 | Day One Biopharmaceuticals Inc | DAWN | 5,200,000 | $48.5M | 1.71% |